This research study is for participants diagnosed with leptomeningeal metastasis disease (LMM), a condition where cancer has spread to the fluid and membranes surround the brain and spinal cord. The purpose of this study is to find out whether a consumer Smartwatch can continuously monitor the participant's health and detect early signs of neurological decline and whether sending an automatic alert to the participant's doctor when a change is detected can help reduce the number of participant hospitalizations.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Predicting Karnofsky Performance Scale (KPS) decline
Timeframe: 6 months
Predicting neurological progression
Timeframe: 6 months
Days in hospital per participant-month during silent monitoring periods
Timeframe: 5 months
Days in hospital per participant-month during active alerting periods
Timeframe: 5 months
Participant completion
Timeframe: 5 months
Recruitment rate
Timeframe: 12 months
Dropout rate
Timeframe: 12 months
Alert pathway feasibility
Timeframe: 5 months